Quick Answer
Aldeyra Therapeutics, Inc. reported Diluted EPS of $0.56 per share (loss) for fiscal year 2025.
Aldeyra Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.56 | +40.4% |
| 2024 | -$0.94 | -46.9% |
| 2023 | -$0.64 | +39.6% |
| 2022 | -$1.06 | +0.9% |
| 2021 | -$1.07 | +23.6% |
| 2015 | -$1.40 | +54.7% |
| 2014 | -$3.09 | +82.5% |
| 2013 | -$17.61 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | +48.0% | +18.8% |
| June 30, 2025 | -$0.16 | +42.9% | +5.9% |
| March 31, 2025 | -$0.17 | -21.4% | +32.0% |
| September 30, 2024 | -$0.25 | -78.6% | +10.7% |
| June 30, 2024 | -$0.28 | -86.7% | -100.0% |
| March 31, 2024 | -$0.14 | +48.1% | +0.0% |
| September 30, 2023 | -$0.14 | +44.0% | +6.7% |
| June 30, 2023 | -$0.15 | +50.0% | +44.4% |
- Aldeyra Therapeutics, Inc. showed an increase of +40.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2013–2025 period, Aldeyra Therapeutics, Inc.’s diluted eps has grown by 96.8% (from $17.61 per share (loss) to $0.56 per share (loss)).
- The most recent figure is from Aldeyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: